Skip Navigation
News and Publications
In This Section      
Print This Page

Current News Releases

Current News Releases

Released: September 16, 2014

Technique will likely have applications in forensic science and donor organ monitoring

Researchers at Johns Hopkins have identified a highly sensitive means of analyzing very tiny amounts of DNA. The discovery, they say, could increase the ability of forensic scientists to match genetic material in some criminal investigations. It could also prevent the need for a painful, invasive test given to transplant patients at risk of rejecting their donor organs and replace it with a blood test that reveals traces of donor DNA.

Released: September 16, 2014

Using a pain clinic as a testing ground, researchers at Johns Hopkins have shown that a management process first popularized by Toyota in Japan can substantially reduce patient wait times and possibly improve the teaching of interns and residents.

Released: September 15, 2014

The timing of a toddler’s first steps is an important developmental milestone, but a slight delay in walking is typically not a cause of concern by itself.

Released: September 15, 2014

Lisa Allen to lead service excellence and patient satisfaction efforts across the academic health care delivery system

Patient service and quality improvement expert Lisa Allen has been named the first chief patient experience officer for Johns Hopkins Medicine.

Released: September 11, 2014

The Johns Hopkins Multiple Sclerosis Center is the recipient of one of 22 research grants offered to investigators in nine countries by the International Progressive MS Alliance, a worldwide collaborative focused on finding solutions to progressive forms of multiple sclerosis (MS).

Released: September 11, 2014

More research is still needed to test the role of psilocybin in helping people quit

 Johns Hopkins researchers report that a small number of longtime smokers who had failed many attempts to drop the habit did so after a carefully controlled and monitored use of psilocybin, the active hallucinogenic agent in so-called "magic mushrooms,” in the context of a cognitive behavioral therapy treatment program.

Released: September 10, 2014

The Johns Hopkins University School of Medicine has been named a top medical education program, along with the University of California, San Francisco, by the physician network Doximity and its partner U.S. News & World Report. This is their first comprehensive national study of residency programs. Johns Hopkins placed in the top 10 in 14 specialties and is number one in four specialties: Nuclear Medicine, Otolaryngology, Pathology (Anatomic & Clinical) and Surgery.

Released: September 10, 2014

Norm Barker, M.A., M.S., a professor of pathology and art as applied medicine at the Johns Hopkins University School of Medicine, and Lydia Gregg, M.A., an instructor and certified medical illustrator at the school, each received an Award of Excellence in the BioCommunications Association’s 2014 BioImages competition.

Released: September 9, 2014

A team of American infectious disease and critical care experts is alerting colleagues caring for Ebola patients that how they remove their personal protective gear can be just as crucial as wearing it to prevent exposure to the deadly virus.

Released: September 9, 2014

Seeks to close gender gap in reproductive health care

Compared with women, American men have worse access to reproductive and sexual health care, research shows, a disparity fueled in part by the lack of standard clinical guidelines on the types and timing of exams, tests and treatments that should be offered to all men of reproductive age. 

Released: September 4, 2014

Prostate cancer patients whose tumors contain a shortened receptor called AR-V7 are less likely to respond to two widely used drugs for metastatic prostate cancer, according to results of a study led by researchers at Johns Hopkins’ Kimmel Cancer Center and Brady Urological Institute. If large-scale studies validate the findings, the investigators say men with detectable blood levels of AR-V7 should avoid these two drugs and instead take other medicines to treat their prostate cancer. A report on the work is described online Sept. 3 in the New England Journal of Medicine.
Released: September 4, 2014

 Three Johns Hopkins Medicine hospitals have been awarded the 2014 Excellence Award for Quality Improvement in Hospitals from the Delmarva Foundation for Medical Care, an independent, nonprofit health care quality improvement organization. The Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center in Baltimore and Sibley Memorial Hospital in Washington, D.C., each earned the distinction.

Released: September 3, 2014

New target identified for treatment of abnormal blood vessels and leakage

Working with mice, a multicenter team of researchers has found a new way to reduce the abnormal blood vessel growth and leakage in the eye that accompany some eye diseases. The finding could lead to the development of new drugs for wet macular degeneration and diabetic macular edema 

Released: September 2, 2014

Research at Johns Hopkins has helped a team of scientists elsewhere identify and develop a compound that could directly target a genetic mutation responsible for a common familial form of amyotrophic lateral sclerosis (ALS) and a biologically related memory-robbing disease known as frontotemporal dementia (FTD). 

Released: August 28, 2014

Experts say child’s relapse and two similar cases can pave way to future cure efforts

The news in July that HIV had returned in a Mississippi toddler after a two-year treatment-free remission dashed the hopes of clinicians, HIV researchers and the public at large tantalized by the possibility of a cure.

Released: August 27, 2014

Animal study holds promise for treating diabetic ulcers and burns

A combination of two drugs already approved by the U.S. Food and Drug Administration for different applications reduces wound healing time by one-quarter and significantly decreases scar tissue in mice and rats, Johns Hopkins researchers report. If the findings, reported in the September issue of the Journal of Investigative Dermatology, hold true in future human studies, the dual treatment could speed skin healing in people with skin ulcers, extensive burns, surgical wounds and battlefield injuries.

Released: August 27, 2014

Simple genetic test predicts dosage needed

Many African-Americans may not be getting effective doses of the HIV drug maraviroc, a new study from Johns Hopkins suggests. The initial dosing studies, completed before the drug was licensed in 2007, included mostly European-Americans, who generally lack a protein that is key to removing maraviroc from the body. The current study shows that people with maximum levels of the protein — including nearly half of African-Americans — end up with less maraviroc in their bodies compared to those who lack the protein even when given the same dose. A simple genetic test for the gene that makes the CYP3A5 protein could be used to determine what doses would achieve effective levels in individuals, the researchers say.

Released: August 26, 2014

Chemical alterations to genes appear key to tumor development

Regardless of their stage or type, cancers appear to share a telltale signature of widespread changes to the so-called epigenome, according to a team of researchers. In a study of a broad variety of cancers, the investigators say they have found widespread and distinctive changes to chemical marks known as methyl groups attached to DNA. Those marks help govern whether genes are turned “on” or “off,” and ultimately how the cell behaves. Such reversible chemical marks on DNA are known as epigenetic, and together they make up the epigenome.

Released: August 25, 2014

Johns Hopkins Medicine Dean and CEO Paul Rothman and Armstrong Institute for Patient Safety and Quality Director Peter Pronovost named to Modern Healthcare’s 100 Most Influential People in Healthcare list

Modern Healthcare, a leading industry publication, has named Johns Hopkins Medicine Dean and CEO Paul B. Rothman, M.D., and patient safety expert Peter J. Pronovost, M.D., Ph.D., to this year’s 100 Most Influential People in Healthcare list. The list recognizes individuals deemed by their peers and experts as leaders in the industry.

Released: August 21, 2014

Additional tool accelerates personalized medicine research

Johns Hopkins stem cell biologists have found a way to reprogram a patient’s skin cells into cells that mimic and display many biological features of a rare genetic disorder called familial dysautonomia. The process requires growing the skin cells in a bath of proteins and chemical additives while turning on a gene to produce neural crest cells, which give rise to several adult cell types. The researchers say their work substantially expedites the creation of neural crest cells from any patient with a neural crest-related disorder, a tool that lets physicians and scientists study each patient’s disorder at the cellular level.

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer